Kyverna Therapeutics (KYTX) Asset Writedowns and Impairment (2025)
Kyverna Therapeutics (KYTX) posted Asset Writedowns and Impairment of $648000.0 for Q1 2025.
Kyverna Therapeutics (KYTX) Asset Writedowns and Impairment (2025) Analysis & Trends
Kyverna Therapeutics' Asset Writedowns and Impairment history runs 1 years deep, the most recent figure standing at $648000.0 for Q1 2025.
- Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $648000.0 in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $648000.0 (changed N/A YoY) and the FY2025 annual result came in at $648000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment was $648000.0 for Q1 2025 at Kyverna Therapeutics.
- Across five years, Asset Writedowns and Impairment topped out at $648000.0 in Q1 2025 and bottomed at $648000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - |
| 2 | Nanobiotix | 1,924.26 Bn | 1,924.20 Bn | - |
| 3 | Akari Therapeutics | 975.59 Bn | 975.59 Bn | - |
| 4 | BeOne Medicines | 471.47 Bn | 466.67 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.76 Bn | 114.52 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.90 Bn | 61.15 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.83 Bn | 62.83 Bn | - |
| 8 | Argenx Se | 55.77 Bn | 50.59 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.45 Bn | 37.45 Bn | - |
| 10 | Kyverna Therapeutics | 486.50 Mn | 486.50 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 648,000.00 |
| Mar 31, 2025 | 648,000.00 |